For general help and advice on putting our guidelines into practice, see resources to help you put NICE guidance into practice. Update information March 2022: We have reviewed the evidence on blood pressure targets for people with cardiovascular disease, and made a new recommendation. This is marked [2022]. We have also reassessed the evidence on antihypertensive drug treatment, and made a new recommendation for people with cardiovascular disease. This is marked [2022]. For recommendations ending [2019, amended 2022], we have not reviewed the evidence for people without cardiovascular disease. We have made minor changes to the wording of the recommendations without changing the intent. For an explanation of these changes, see the rationale and impact section on blood pressure targets for people with cardiovascular disease. August 2019: We have reviewed the evidence and made new recommendations on diagnosis, monitoring and drug treatment for hypertension, and identifying who to refer for same-day specialist review. These recommendations are marked [2019]. We have also made some changes without an evidence review: the information on cuff size for measuring blood pressure was moved to avoid repetition plasma glucose testing was replaced with glycated haemoglobin (HbA1C) to reflect current practice a note was added because of concerns about the risks of salt substitutes in some groups the information on when to refer to the hypertension in pregnancy guideline was made clearer. These recommendations are marked [2004, amended 2019] or [2011, amended 2019]. evidence review in that year. In some cases minor changes have been made to the wording to bring the language and style up to date, without changing the meaning. Recommendations 1.2.11 and 1.4.24 (marked [2009]) were originally published in section 1.4 of NICE's guideline on type 2 diabetes in adults, which was updated by this guideline. 